Literature DB >> 15657787

Intracranial peripheral primitive neuroectodermal tumor manifesting as abducens nerve palsy.

N Horinaka1, Y Ito, M Miyajima, M Hishii, K Suzuki, M Saito, H Arai.   

Abstract

INTRODUCTION: Peripheral primitive neuroectodermal tumor (PNET) occurring as an extra-axial lesion within the intracranial space and extending to the subarachnoid space is extremely rare. CASE REPORT: An 18-month-old girl presented with an intracranial peripheral PNET manifesting as abducens nerve palsy. Magnetic resonance imaging on admission revealed a lesion affecting the trigeminal and abducens nerves. The tumor was partially removed via the subtemporal approach. Histological examination showed a high-grade, undifferentiated neoplasm of small cell type with positive immunostaining for MIC2. The histological diagnosis was peripheral PNET. OUTCOME: Craniospinal radiotherapy reduced the tumor size, but adjuvant chemotherapy designed for Ewing's sarcomas and PNETs was not effective. She died 1 month after the last chemotherapy, despite whole craniospinal irradiation (total dose 53.2 Gy) and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657787     DOI: 10.1007/s00381-004-1053-9

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  20 in total

1.  Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy.

Authors:  S Gururangan; N M Marina; X Luo; D M Parham; C Y Tzen; C A Greenwald; B N Rao; L E Kun; W H Meyer
Journal:  J Pediatr Hematol Oncol       Date:  1998 Jan-Feb       Impact factor: 1.289

2.  Ewing's sarcoma--routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study.

Authors:  E J Perlman; P S Dickman; F B Askin; H E Grier; J S Miser; M P Link
Journal:  Hum Pathol       Date:  1994-03       Impact factor: 3.466

3.  Peripheral-type primitive neuroectodermal tumor arising in the tentorium. Case report.

Authors:  Y Katayama; S Kimura; T Watanabe; A Yoshino; M Koshinaga
Journal:  J Neurosurg       Date:  1999-01       Impact factor: 5.115

4.  Intracranial Ewing sarcoma/'peripheral' primitive neuroectodermal tumor of dural origin with molecular genetic confirmation.

Authors:  N L Antunes; A Lellouch-Tubiana; C Kalifa; O Delattre; A Pierre-Kahn; M K Rosenblum
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

5.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Authors:  Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

Review 6.  Peripheral and central primitive neuroectodermal tumors. A nosologic concept seeking a consensus.

Authors:  L P Dehner
Journal:  Arch Pathol Lab Med       Date:  1986-11       Impact factor: 5.534

7.  Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma. A report from the Kiel Pediatric Tumor Registry.

Authors:  D Schmidt; C Herrmann; H Jürgens; D Harms
Journal:  Cancer       Date:  1991-11-15       Impact factor: 6.860

8.  Prognostic value of histopathology in Ewing's sarcoma. Long-term follow-up of distal extremity primary tumors.

Authors:  K R Hartman; T J Triche; T J Kinsella; J S Miser
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

Review 9.  Ewing's sarcoma and extracranial primitive neuroectodermal tumors.

Authors:  L Granowetter
Journal:  Curr Opin Oncol       Date:  1992-08       Impact factor: 3.645

10.  Primary meningeal tumors in children: correlation of clinical and CT findings with histologic type and prognosis.

Authors:  J K Hope; D A Armstrong; P S Babyn; R R Humphreys; D C Harwood-Nash; S H Chuang; P V Marks
Journal:  AJNR Am J Neuroradiol       Date:  1992 Sep-Oct       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.